Salvage Chemotherapy for Metastatic Breast Cancer

Cold S. , Jensen N.V. , Brincker H. . The influence of chemotherapy on survival after recurrence in breast cancer: a population-based study of patients treated in the 1950s, 1960s, and 1970s. Eur J Cancer. 1993; 29A: 1146–1152.

Vogel C.L. , Azevedo S. , Hilsenbeck S. . Survival after first recurrence of breast cancer: the Miami experience. Cancer. 1992; 70: 129–135.

Henderson I.C. , Berry D. , Demetri G. . Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 101a. Abstract.

Valero V. , Jones S.E. , Von Hoff D.D. . A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998; 16: 3362–3368.

Fazeny B. , Zifko U. , Meryn S. . Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: a phase II study. Cancer Chemother Pharmacol. 1996; 39: 150–156.

Livingston R.B. , Ellis G.K. , Gralow J.R. . Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997; 15: 1395–1400.

Seidman A.D. , Hochhauser D. , Gollub M. . Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14: 1877–1884.

Ragaz J. , Campbell C. , Gelmon K. . Can patients with metastatic breast cancer (MBC) pretreated with cyclophosphamide (C), anthracyclines (A) or taxol (Tax) respond to infusions of 5-FU (FUI)? Breast Cancer Res Treat. 1997; 46: 95. Abstract 411.

Perez E.A. , Irwin D.H. , Patel R. . A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 480A. Abstract.

Cobleigh M.A. , Vogel C.L. , Tripathy D. . Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 227 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 376a. Abstract.

Fornier M. , Seidman A.D. , Esteva F.J. . Weekly (W) Herceptin (H) + 1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2–) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 126a. Abstract.

Löffler T.M. , Freund W. , Dröge C. . Activity of weekly Taxotere in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 113a. Abstract.

Burstein H.J. , Younger J. , Bunnell C.A. . Weekly docetaxel (Taxotere) for metastatic breast cancer: a phase II trial. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 127a. Abstract 485.

Nabholtz J.M. , Thuerlimann B. , Beswoda W.R. . Taxotere improves survival over mitomycin-C vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen: final results of a phase III randomized trial. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 101a. Abstract.

Blum J.L. , Jones S.E. , Buzdar A.U. . A multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17: 485–493.

Blum J.L. , Buzdar A.M. , Dieras V. . A multicenter phase II trial of Xeloda (capecitabine) in taxane-refractory metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 107a. Abstract.

Hortobagyi G. . New cytotoxic agents for the treatment of breast cancer. Oncology. 1996; 10(suppl 6): 21–29.

Carmichael J. , Possinger K. , Phillip P. . Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995; 13: 2731–2736.

Spielman M. , Kalla S. , Llombart-Cussac A. . Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer. 1997; 33(suppl 8): A663. Abstract.

Blackstein M. , Vogel C.L. , Ambinder R. . Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer. 1997; 33(suppl 8): A664. Abstract.

Martin M. , Spielman M. , Namer M. . MTA (multitargeted antifolate LY231514) in metastatic breast cancer patients (pts) with prior anthracycline exposure: a European phase II study. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 113a. Abstract.

Joensuu H. , Holli K. , Heikkinen M. . Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998; 16: 3720–3730.

Sledge G.W. , Neuberg D. , Ingle J. . Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Annu Meet Am Soc Clin Oncol. 1997; 16: 1a. Abstract.